EUCTR2020-001305-23-SE进行中（未招募）1 期
A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen
- 入组人数
- 136
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •All Subprotocols
- •- Subjects with mCRPC with histologically or cytologically confirmed adenocarcinoma of the prostate without pure neuroendocrine differentiation or small cell features
- •- Subjects must have undergone bilateral orchiectomy or must be on continuous androgen deprivation therapy with a gonadotropin releasing hormone agonist or antagonist.
- •- Total serum testosterone = 50 ng/dL (or 1.7 nmol/L)
- •- Eastern Cooperative Oncology Group (ECOG) performance status of 0 – 1
- •- Life expectancy of > 3 months
- •- Adequate organ function, defined as follows:
- •absolute neutrophil count = 1.5 x 10^9/L (without growth factor support within 7 days from screening assessment)
- •platelet count = 100 x 10^9/L (without platelet transfusion within 7 days from screening assessment)
- •hemoglobin > 9 g/dL (90 g/L) (subprotocol A, C & D) / > 10 g/dL (100g/L) (subprotocol B) (without blood transfusion within 7 days from screening assessment)
- •estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) calculation = 30 mL/min/1.73 m2
- •AST and ALT < 3 x upper limit of normal (ULN) (or < 5 x ULN for subjects with liver involvement)
- •total bilirubin (TBL) < 1.5 x ULN (or < 2 x ULN for subjects with liver metastases)
- •left ventricular ejection fraction (LVEF)> 50% (2-D transthoracic echocardiogram [ECHO] is the preferred method of evaluation; multi-gated acquisition scan is acceptable if ECHO is not available)
- •- Baseline electrocardiogram (ECG) QTc = 470 msec
- •Subprotocol A & B only
- •- Subjects planning to receive enzalutamide (subprotocol A) / abiraterone (subprotocol B) for the first time for mCRPC (subjects who received prior enzalutamide (subprotocol A) / abiraterone (subprotocol B) are not eligible).
- •Subprotocol C only
- •- Subjects who are refractory to a novel antiandrogen therapy (abiraterone, apalutamide, and/or enzalutamide) given for metastatic or non-metastatic prostate cancer. Subjects must be ineligible for or refuse taxane therapy.
- •- Evidence of progressive disease, defined as 1 or more PCWG3 criteria:
- •PSA level of at least 1 ng/mL that has risen on at least 2 successive occasions at least 1 week apart
- •nodal or visceral progression as defined by RECIST 1.1 with PCGW3 modifications
- •appearance of 2 or more new lesions in bone scan
- •Subprotocol D only
- •- Subjects may have had novel hormonal therapies (NHT; eg,
- •abiraterone, enzalutamide, apalutamide or darolutamide) for prostate
- •cancer, but no more than 1 NHT for metastatic prostate cancer.
- •- Subjects must be ineligible for or refuse taxane therapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 69
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 67
排除标准
- •All Subprotocols
- •- CNS metastases/leptomeningeal disease
- •- Symptomatic peripheral sensory/motor neuropathy =grade3
- •- History/presence of clinically relevant CNS pathology
- •- Confirmed history/current autoimmune disease or other diseases resulting in permanent immunosuppression/requiring permanent immunosuppressive therapy
- •- Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials (Subprot.A,B&D) /active fungal, bacterial, viral, or other infection requiring systemic therapy (Subprot.C) within 7days of dosing
- •- History/evidence of inflammatory bowel disease or any other GI disorder causing chronic nausea, vomiting, or diarrhea
- •- History of arterial/venous thrombosis within 12months of 1st dose
- •- Myocardial infarction, uncontrolled hypertension (Subprot.A,C&D), unstable angina, cardiac arrhythmia requiring medication, &/or symptomatic congestive heart failure (NYHA > class II) within 12months (Subprot.A,B&D) /within 6months (Subprot.C) of 1st dose of AMG160
- •- Unresolved toxicities from prior anti-tumor therapy not having resolved to CTCAE version 5.0 grade 1, except for alopecia or toxicities that are stable and well-controlled & there is agreement to allow by both the investigator & sponsor
- •- Known HIV infection, hepatitis C or hepatitis B infection
- •- History of other malignancy within the past 2years, with the following exceptions:
- •Malignancy treated with curative intent & with no known active disease present for =3 years before enrollment and felt to be at low risk for recurrence by treating physician
- •Adequately treated non-melanoma skin cancer/lentigo maligna without evidence of disease
- •Adequately treated urothelial papillary noninvasive carcinoma/carcinoma in situ
- •- Prior treatment with a taxane for mCRPC
- •- Radiation therapy within 4weeks of 1st dose (or local or focal radiotherapy within 2weeks)
- •- Any anticancer therapy/immunotherapy within 4weeks (2weeks Subprot.C) of start of 1st dose, not including LHRH/GnRH analogue. Subjects on a stable bisphosphonate/denosumab regimen for =30 days prior to enrollment are eligible
- •- Prior PSMAxCD3 bispecific therapy (not subprot.C part3)
- •- Requiring chronic systemic corticosteroid therapy/any other immunosuppressive therapies. Low dose corticosteroids permitted
- •- Prior major surgery within 4weeks of 1st dose
- •- Currently receiving treatment in another investigational device/drug study, or <4 weeks since ending treatment on another investigational device or drug study
- •- Male subjects with a female partner of childbearing potential/pregnant partner who are unwilling to practice sexual abstinence/use contraception during treatment and for an additional 4months (Subprot.A&B)/8months (Subprot.C) after the last dose
- •- Male subjects unwilling to abstain from donating sperm during treatment and for an additional 4 months (Subprot.A,B&D)/8months (Subprot.C) after the last dose
- •- Subject has known sensitivity to any of the products (or components) to be administered during dosing
- •- Subject likely to not be available to complete all protocol-required study visits/procedures, &/or to comply with all required study procedures
- •- History/evidence of any other clinically significant disorder, condition or disease (except for those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
- •- History of SARS-CoV-2 infection unless agreed upon
研究者
相似试验
撤回
不适用
A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC);-Subprotocol A: A Phase 1b Study Evaluating the Safety and Efficacy of AMG 160 in Combination With Enzalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC) -Subprotocol B: A Phase 1b Study Evaluating the Safety and Efficacy of AMG 160 in Combination With Abiraterone in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)prostate cancerprostaat kankerMetastatic Castration-resistant10036958NL-OMON54909Amgen6
进行中（未招募）
1 期
A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate CancerMedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 100000004864EUCTR2020-001305-23-DEAmgen129
进行中（未招募）
1 期
A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate CancerMedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 100000004864EUCTR2020-001305-23-DKAmgen136
进行中（未招募）
1 期
A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate CancerMedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 100000004864EUCTR2020-001305-23-ITAMGEN INC.105
进行中（未招募）
1 期
A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate CancerEUCTR2020-001305-23-NLAmgen105